Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
FDF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-(cyclopropylmethoxy)-4-(4-methylsulfonylphenyl)-5,5-dimethylfuranone
2. Equioxx
3. Ml 1,785,713
4. Ml 1785713
5. Ml-1,785,713
6. Ml-1785713
7. Ml1,785,713
8. Ml1785713
1. 189954-96-9
2. Equioxx
3. Previcox
4. Librens
5. Ml 1785713
6. 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)furan-2(5h)-one
7. 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one
8. Ml-1,785,713
9. Nsc-758895
10. Y6v2w4s4wt
11. Chembl69998
12. Chebi:76136
13. Firocoxib (ema Epar: Veterinary)
14. Equixx
15. Ml-1785713
16. 3-(cyclopropylmethoxy)-4-(4-methylsulfonylphenyl)-5,5-dimethylfuranone
17. 2(5h)-furanone, 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-
18. 2(5h)-furanone, 3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-
19. 3-(cyclopropylmethoxy)-4-(4-methanesulfonylphenyl)-5,5-dimethyl-2,5-dihydrofuran-2-one
20. Firocoxib [usan:inn]
21. Unii-y6v2w4s4wt
22. Firocoxibum
23. 3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-2(5h)-furanone
24. 3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2(5h)-one
25. Firocoxib [inn]
26. Firocoxib [mi]
27. Firocoxib (usan/inn)
28. Firocoxib [usan]
29. Firocoxib [mart.]
30. Equioxx (tn) [veterinary]
31. Firocoxib [green Book]
32. Amy378
33. Schembl1383179
34. Dtxsid40870188
35. Hms3264g15
36. Pharmakon1600-01504526
37. Bcp07253
38. Zinc3623447
39. Bdbm50080082
40. Nsc758895
41. Ccg-213396
42. Cs-3419
43. Db09217
44. Nsc 758895
45. Ncgc00389572-01
46. Ncgc00389572-02
47. Ac-33540
48. As-73802
49. Hy-14670
50. Sbi-0206717.p001
51. Ft-0668544
52. Firocoxib, Vetranal(tm), Analytical Standard
53. C18363
54. C73637
55. D03712
56. Ab01563063_01
57. 954f969
58. A918990
59. Sr-01000872758
60. J-012265
61. Q2034390
62. Sr-01000872758-1
63. 3-(cyclopropylmethoxy)-4-(4-methylsulfonyl)phenyl)-5,5-dimethylfuranone
64. 3-(cyclopropylmethoxy)-4-[4-(methanesulfonyl)phenyl]-5,5-dimethylfuran-2(5h)-one
65. 3-cyclopropylmethoxy-4-(4-methanesulfonyl-phenyl)-5,5-dimethyl-5h-furan-2-one
| Molecular Weight | 336.4 g/mol |
|---|---|
| Molecular Formula | C17H20O5S |
| XLogP3 | 2.2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Exact Mass | 336.10314491 g/mol |
| Monoisotopic Mass | 336.10314491 g/mol |
| Topological Polar Surface Area | 78 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 614 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Used for the treatment of pain inflammation and fever in horses and dogs.
* Tablets:
For the relief of pain and inflammation associated with osteoarthritis in dogs.
For the relief of postoperative pain and inflammation associated with soft-tissue, orthopaedic and dental surgery in dogs.
* Oral paste:
Alleviation of pain and inflammation associated with osteoarthritis and reduction of associated lameness in horses.
Alleviation of pain and inflammation associated with osteoarthritis and reduction of associated lameness in horses.
QM01AH90
QM01AH90
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Surfactant & Foaming Agents
Fillers, Diluents & Binders
Thickeners and Stabilizers
Parenteral
Film Formers & Plasticizers
Rheology Modifiers
Coating Systems & Additives
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Firocoxib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Firocoxib, including repackagers and relabelers. The FDA regulates Firocoxib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Firocoxib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Firocoxib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Firocoxib supplier is an individual or a company that provides Firocoxib active pharmaceutical ingredient (API) or Firocoxib finished formulations upon request. The Firocoxib suppliers may include Firocoxib API manufacturers, exporters, distributors and traders.
click here to find a list of Firocoxib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Firocoxib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Firocoxib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Firocoxib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Firocoxib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Firocoxib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Firocoxib suppliers with NDC on PharmaCompass.
Firocoxib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Firocoxib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Firocoxib GMP manufacturer or Firocoxib GMP API supplier for your needs.
A Firocoxib CoA (Certificate of Analysis) is a formal document that attests to Firocoxib's compliance with Firocoxib specifications and serves as a tool for batch-level quality control.
Firocoxib CoA mostly includes findings from lab analyses of a specific batch. For each Firocoxib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Firocoxib may be tested according to a variety of international standards, such as European Pharmacopoeia (Firocoxib EP), Firocoxib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Firocoxib USP).
LOOKING FOR A SUPPLIER?
